v3.26.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Millions
Sep. 26, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 5,461 $ 9,852
Short-term investments 600 253
Accounts receivable, less allowances of $135 and $147 9,625 8,900
Inventories 5,643 5,425
Contract assets, net 1,691 1,666
Other current assets 2,595 2,612
Total current assets 25,615 28,707
Property, plant and equipment, net 10,577 10,565
Acquisition-related intangible assets, net 18,077 15,838
Other assets 5,701 5,871
Goodwill 54,263 49,362
Total assets 114,233 110,343
Current liabilities:    
Short-term obligations and current maturities of long-term obligations 2,262 3,533
Accounts payable 3,087 3,622
Accrued payroll and employee benefits 2,069 1,995
Contract liabilities 2,941 2,710
Other accrued expenses 3,811 3,329
Total current liabilities 14,170 15,189
Deferred income taxes 1,473 1,493
Other long-term liabilities 4,586 4,273
Long-term obligations 39,108 35,852
Redeemable noncontrolling interest 128 122
Thermo Fisher Scientific Inc. shareholders’ equity:    
Preferred stock, $100 par value, 50,000 shares authorized; none issued 0 0
Common stock, $1 par value, 1,200,000,000 shares authorized; 446,511,736 and 445,160,301 shares issued 447 445
Capital in excess of par value 19,247 18,563
Retained earnings 63,740 59,156
Treasury stock at cost, 75,995,868 and 68,938,831 shares (26,408) (22,309)
Accumulated other comprehensive income/(loss) (2,264) (2,448)
Total Thermo Fisher Scientific Inc. shareholders’ equity 54,761 53,407
Noncontrolling interests 6 7
Total equity 54,767 53,415
Total liabilities, redeemable noncontrolling interest and equity $ 114,233 $ 110,343